Manufacturers submit market authorisation application to FDA for upadacitinib for ankylosing spondylitis

Evidence for use of this JAK1-selective inhibitor in ankylosing spondylitis comes from the SELECT-AXIS 1 study which found that 52% achieved an ASAS40 response vs 26% for placebo (p<0.001). A market authorisation application has yet to be filed in the EU.

Source:

Biospace Inc.